Differences in flurbiprofen pharmacokinetics betweenCYP2C9*1/*1,*1/*2, and*1/*3genotypesCraig R. Lee; John A. Pieper; Reginald F. Frye; Alan L. Hinderliter; Joyce A. Blaisdell; Joyce A. Goldstein · 2003

Losartan and E3174 Pharmacokinetics in Cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 IndividualsCraig R. Lee; John A. Pieper; Alan L. Hinderliter; Joyce A. Blaisdell; Joyce A. Goldstein · 2003

Cloning and Expression of Murine CYP2Cs and Their Ability to Metabolize Arachidonic AcidGang Luo; Darryl C. Zeldin; Joyce A. Blaisdell; Ernest Hodgson; Joyce A. Goldstein · 1998

Genetic Polymorphisms in Human Drug Metabolic EnzymesMark Steven Miller; Deborah Gail McCarver; Douglas A. Bell; David L. Eaton; Joyce A. Goldstein · 1997

Experimental hepatic porphyria induced by polychlorinated biphenylsJoyce A. Goldstein; Patricia Hickman; Danny L. Jue · 1974

Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2CsTheresa S. Klose; Joyce A. Blaisdell; Joyce A. Goldstein · 1999

Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in HumansLee, Craig R.; Pieper, John A.; Hinderliter, Alan L.; Frye, Reginald F.; Blaisdell, Joyce A.; Goldstein, Joyce A. · The Journal of Clinical Pharmacology · 2003

Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamilyRomkes, Marjorie; Faletto, Michael B.; Blaisdell, Joyce A.; Raucy, Judy L.; Goldstein, Joyce A. · Biochemistry · 1991